Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (USRLD: Entresto ® tablets).

Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization.

The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).